Hyperion Cuts Its Losses After Andromeda Deception
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech revealed that its recently closed acquisition was conducted under false pretenses and that Andromeda employees had been manipulating clinical trial data for the late-stage type 1 diabetes drug.